These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38215341)

  • 21. Neurofilament as a potential biomarker for spinal muscular atrophy.
    Darras BT; Crawford TO; Finkel RS; Mercuri E; De Vivo DC; Oskoui M; Tizzano EF; Ryan MM; Muntoni F; Zhao G; Staropoli J; McCampbell A; Petrillo M; Stebbins C; Fradette S; Farwell W; Sumner CJ
    Ann Clin Transl Neurol; 2019 May; 6(5):932-944. PubMed ID: 31139691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SMA-MAP: a plasma protein panel for spinal muscular atrophy.
    Kobayashi DT; Shi J; Stephen L; Ballard KL; Dewey R; Mapes J; Chung B; McCarthy K; Swoboda KJ; Crawford TO; Li R; Plasterer T; Joyce C; ; Chung WK; Kaufmann P; Darras BT; Finkel RS; Sproule DM; Martens WB; McDermott MP; De Vivo DC; ; Walker MG; Chen KS
    PLoS One; 2013; 8(4):e60113. PubMed ID: 23565191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls.
    Wadman RI; Stam M; Jansen MD; van der Weegen Y; Wijngaarde CA; Harschnitz O; Sodaar P; Braun KP; Dooijes D; Lemmink HH; van den Berg LH; van der Pol WL
    PLoS One; 2016; 11(11):e0167087. PubMed ID: 27893852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of plasma neurofilament light chain for monitoring efficacy in children with later-onset spinal muscular atrophy under nusinersen treatment.
    Jin J; Feng Y; Huang S; Cui Y; Jiang L; Yan Y; Yu Y; Zhou D; Gao F; Mao S
    Clin Chem Lab Med; 2024 May; 62(6):e132-e135. PubMed ID: 38373071
    [No Abstract]   [Full Text] [Related]  

  • 25. Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.
    Hjartarson HT; Nathorst-Böös K; Sejersen T
    Drug Des Devel Ther; 2022; 16():1865-1883. PubMed ID: 35734367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study.
    Kariyawasam DS; D'Silva AM; Sampaio H; Briggs N; Herbert K; Wiley V; Farrar MA
    Lancet Child Adolesc Health; 2023 Mar; 7(3):159-170. PubMed ID: 36669516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
    Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O
    Neuromuscul Disord; 2019 Jan; 29(1):21-29. PubMed ID: 30553700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies.
    Angilletta I; Ferrante R; Giansante R; Lombardi L; Babore A; Dell'Elice A; Alessandrelli E; Notarangelo S; Ranaudo M; Palmarini C; De Laurenzi V; Stuppia L; Rossi C
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen.
    Paris A; Bora P; Parolo S; MacCannell D; Monine M; van der Munnik N; Tong X; Eraly S; Berger Z; Graham D; Ferguson T; Domenici E; Nestorov I; Marchetti L
    CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):196-206. PubMed ID: 36471456
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Saffari A; Cannet C; Blaschek A; Hahn A; Hoffmann GF; Johannsen J; Kirsten R; Kockaya M; Kölker S; Müller-Felber W; Roos A; Schäfer H; Schara U; Spraul M; Trefz FK; Vill K; Wick W; Weiler M; Okun JG; Ziegler A
    Orphanet J Rare Dis; 2021 Oct; 16(1):441. PubMed ID: 34670613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Genetic tests and clinical re-evaluation of 85 children with suspected spinal muscular atrophy].
    Ji X; Liu XQ; Shen JW; Li XH; Tao J
    Zhonghua Er Ke Za Zhi; 2010 Jun; 48(6):425-30. PubMed ID: 21055263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSF IL-8 Associated with Response to Gene Therapy in a Case Series of Spinal Muscular Atrophy.
    Verma S; Perry K; Razdan R; Howell JC; Dawson AL; Hu WT
    Neurotherapeutics; 2023 Jan; 20(1):245-253. PubMed ID: 36289175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases.
    Palermo G; Mazzucchi S; Della Vecchia A; Siciliano G; Bonuccelli U; Azuar C; Ceravolo R; Lista S; Hampel H; Baldacci F
    Mol Neurobiol; 2020 Nov; 57(11):4667-4691. PubMed ID: 32772223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Risdiplam for the treatment of spinal muscular atrophy].
    Vlodavets DV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
    Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ
    Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spinal muscular atrophy in Ghanaian children confirmed by molecular genetic testing: a case series.
    Hammond CK; Oppong E; Ameyaw E; Dogbe JA
    Pan Afr Med J; 2023; 46():78. PubMed ID: 38282771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on Biomarkers in Spinal Muscular Atrophy.
    Pino MG; Rich KA; Kolb SJ
    Biomark Insights; 2021; 16():11772719211035643. PubMed ID: 34421296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.
    Feldkötter M; Schwarzer V; Wirth R; Wienker TF; Wirth B
    Am J Hum Genet; 2002 Feb; 70(2):358-68. PubMed ID: 11791208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study.
    van der Ende EL; Meeter LH; Poos JM; Panman JL; Jiskoot LC; Dopper EGP; Papma JM; de Jong FJ; Verberk IMW; Teunissen C; Rizopoulos D; Heller C; Convery RS; Moore KM; Bocchetta M; Neason M; Cash DM; Borroni B; Galimberti D; Sanchez-Valle R; Laforce R; Moreno F; Synofzik M; Graff C; Masellis M; Carmela Tartaglia M; Rowe JB; Vandenberghe R; Finger E; Tagliavini F; de Mendonça A; Santana I; Butler C; Ducharme S; Gerhard A; Danek A; Levin J; Otto M; Frisoni GB; Cappa S; Pijnenburg YAL; Rohrer JD; van Swieten JC;
    Lancet Neurol; 2019 Dec; 18(12):1103-1111. PubMed ID: 31701893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel challenges in spinal muscular atrophy - How to screen and whom to treat?
    Saffari A; Kölker S; Hoffmann GF; Weiler M; Ziegler A
    Ann Clin Transl Neurol; 2019 Jan; 6(1):197-205. PubMed ID: 30656198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.